Latest Anticoagulants Stories
The DrugNews Center is the web’s largest source for prescription drug warnings, research and legal news.
LONDON, April 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Surveyed MCOs Indicate That Tier Position of Pradaxa and Eliquis Unlikely to Change Even With Addition of VTE Treatment to Label, According to Findings from Decision Resources Group BURLINGTON,
MUNICH, Germany, April 2, 2014 /PRNewswire/ -- For European Media Only, Not for UK Media Atrial fibrillation (AF) is the most common heart rhythm
RARITAN, N.J., March 31, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today it is adding three new clinical trials to its EXPLORER global cardiovascular research
First patient enrolled in largest planned phase 3 study evaluating a novel oral anticoagulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion PARSIPPANY, N.J.,
- Subgroup analyses of East Asian populations from two phase 3 studies, ENGAGE AF-TIMI 48 and Hokusai-VTE, showed consistent results compared to the global study populations from these trials(1,2,3,4) TOKYO,
Results Show Highest Rate of Control Ever Observed with Warfarin in Real-world Setting, Surpassing Thresholds for Cost-Effectiveness of Newer Agents Identified in Five Recent Independent Studies
REG2 Extends Regado's Next-Generation Anticoagulation Therapy Franchise as Phase 3 REGULATE-PCI Clinical Trial of REG1 Advances BASKING RIDGE, N.J., Feb.
DUBLIN, February 5, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/vgwhc9/new_oral) has announced the addition of the "Concise Analysis
- In Roman antiquity, the return of a person who had been banished, or taken prisoner by an enemy, to his old condition and former privileges.
- In international law, that right by virtue of which persons and things taken by an enemy in war are restored to their former status when coming again under the power of the nation to which they belonged.